Matthew Grimmer, PhD

Research interests: The genomic and epigenomic evolution of IDH-mutant glioma, an incurable brain cancer
Other interests: Photography, philanthropy, politics, gardening, wilderness, SCUBA, capsaicin, passport stamps, port wine
Email: matthew.grimmer@ucsf.edu

IDH-mutant glioma is among the most common brain cancers. After initial surgery and chemotherapy, tumors inevitably recur and progress to aggressive high-grade disease. Using several layers of genetic and epigenetic data from matched initial and recurrent tumor samples, I am investigating how IDH-mutant gliomas evade chemotherapy and recur. Comparing specific and genome-wide trends with rich clinical data from each patient, my primary focus is on the driving forces behind chemotherapy-induced genetic hypermutation, a common yet poorly understood resistance mechanism. With exceptionally high mutational burden, hypermutated glioma recurrences suggest a rich pool of putative targets for both targeted therapy and immunotherapy.

Social Media:
LinkedIn >
Google Scholar >
ResearchGate >